The Neitz Labs are developing genetic tests and treatments for common vision disorders, and investigating the retinal circuitry for vision.
Jay and Maureen Neitz collaborate in their studies of the visual system, taking a multidisciplinary approach that uses techniques ranging from molecular genetics to human and animal psychophysics. Major focus areas include developing gene therapy for cone-based vision disorders, investigating the role of genetic variability in the cone photopigments in common eye diseases including AMD, myopia, and glaucoma, understanding the physiological basis for color perception. In addition, the Neitzes are developing genetic tests to identify individuals at risk for developing common eye diseases so that therapeutic interventions can be started before symptoms appear.
Frequently Asked Questions
No. The treatment was successful in an animal model, and the Neitzes are continuing their efforts to translate the treatment from animals to humans. Check back here for updates on progress.
The research necessary to translate the cure for colorblindness to humans is ongoing. At present, there is no FDA clinical trial in humans. Please check back or visit our website, www.neitzvision.com, for more information and updates.
